Neurocrine Biosciences said on Monday its drug failed to meet the main goal in a late-stage clinical trial in patients with a type of disorder that disrupts the brain's ability to control muscles.

Aficamten, a first-in-class cardiac myosin inhibitor, offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed ...

Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...

The FDA approved Addyi (flibanserin), a libido-enhancing drug, in postmenopausal women under the age of 65. Experts explain ...

The FDA expanded its approval of Addyi to treat low libido in postmenopausal women up to age 65. The approval will open up ...